Industry Trends Heart failure affects over five million people annually in the U.S. alone and is the costliest cardiovascular illness, with upwards of $30 billion spent on managing heart failure each year. Cardiac rhythm management devices, such as pacemakers, ICDs and CRT devices, are implanted in patients with arrhythmias to correct cardiac pacing and/or to
The total market for cardiac rhythm management devices in Europe is growing at a rate of 3.9%, which will take the 2018 market value of €2.2 billion up to €2.9 billion by 2025. Reprocessed diagnostic electrophysiology (EP) catheters accounted for a significant percentage of all diagnostic EP catheters used. Reprocessed catheters have a much lower
In 2018, the total market for cardiac rhythm management, electrophysiology and ablation devices experienced an increase over the previous year. Since these devices are critical life-saving apparatuses, the aging U.S. population means continued market growth for all market segments in this report, with particularly strong growth in the electrophysiology (EP) and ablation markets. Over the
The global cardiac leads market size is expected to reach over $2,197 million by 2025, with the left ventricular (LV) lead market segment showing the highest growth. The majority of the global cardiac leads market share was controlled by Medtronic, Abbott, and Boston Scientific. Overall, this global market research includes an analysis ofcardiac leads companies spawning across more than 70 countries in the world.